National Comprehensive Cancer Network



About NCCN

NCCN Flash Update: NCCN Guidelines and Compendium Updated

Flash Update Sent Febuary 1, 2011

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Breast Cancer Risk Reduction. These NCCN Guidelines™ are currently available as Version 1.2011.

  • The option of raloxifene was de-emphasized in the guidelines for postmenopausal women desiring non-surgical risk reduction therapy and included in a footnote that says "Utility of tamoxifen or raloxifene for breast cancer risk reduction in women under 35 years of age is unknown. Raloxifene is only for post-menopausal women > 35 y. While raloxifene in long-term follow-up appears to be less efficacious in risk reduction than tamoxifen, consideration of toxicity may still lead to the choice of raloxifene over tamoxifen in women with an intact uterus."
  • The panel also clarified in a new footnote that routine endometrial ultrasound and biopsy are not recommended for women on tamoxifen therapy in the absence of other symptoms.

NCCN has published updates to the NCCN Guidelines for Central Nervous System Cancers. These NCCN Guidelines are currently available as Version 2.2011

  • The Discussion section of the NCCN Guidelines for Central Nervous System Cancers has been updated to correspond with the treatment algorithms.


For the complete updated version of these and all NCCN Guidelines, visit NCCN.org.

Quick Links


About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us

275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0280
Copyright © 2013 National Comprehensive Cancer Network, All Rights Reserved